Ixazomib bulk supplier for pharma manufacturers

Ixazomib 2.3 mg, 3 mg, 4 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 2.3 mg, 3 mg, 4 mg

Reference Brands: Ninlaro® (EU & US)

Ixazomib Capsules (brand name Ninlaro®) are oral proteasome inhibitors used in multiple myeloma treatment. Available in 2.3 mg, 3 mg, and 4 mg strengths, they are approved in the US and EU and manufactured under GMP standards, offering a convenient and reliable oncology option for B2B pharma partners.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ixazomib? List it or send an offer →

Product Description: Ixazomib Capsules, marketed under the brand name Ninlaro®, are a novel oral proteasome inhibitor used in combination therapies for multiple myeloma in patients who have received at least one prior treatment. Ixazomib works by blocking the 20S proteasome, disrupting protein homeostasis in cancer cells and promoting apoptosis. Available in 2.3 mg, 3 mg, and 4 mg capsule strengths, it provides a convenient oral option for patients and physicians. Manufactured under GMP-compliant facilities, Ixazomib is approved in both the US and EU markets, making it an attractive and effective B2B oncology solution for global pharmaceutical supply chains.

Ixazomib — third party manufacturing & bulk supply

Ixazomib 2.3 mg, 3 mg, 4 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ixazomib is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ixazomib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ixazomib →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Ixazomib is listed as Capsules in 2.3 mg, 3 mg, 4 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ixazomib is referenced against Ninlaro® (EU & US). Reference brands are shown for identification only and remain the property of their respective trademark owners.